FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Special Report

Top 10 biopharma deals of 2009

If there was a hot trend for 2009 biopharma buyouts, it was the mega-merger. Three of the industry's biggest players--Wyeth, Genentech and Schering-Plough--were swept off the map in the first quarter of 2009, as Pfizer, Roche and Merck absorbed them into the fold. The rest of 2009's top deals were considerably smaller. Click here to begin the report and see the full list of the top 10 deals in biotech and pharma. Article

Top Headlines

Eli Lilly chief sees pay hike of 30%

Roll up your sleeves, folks. It's time once again to dig through the numbers on executive pay. First up: Eli Lilly chief John Lechleiter. According to figures disclosed in a regulatory filing, Lechleiter scored a hefty raise in 2009. A really hefty raise, in fact: More than 30 percent. Article

Slideshow

FDA approvals of 2009

New DrugsWelcome to our look back at the new drug approvals of 2009. Last year the FDA gave the green light to 26 new therapies, slightly beating the 2008 total of 25. Of those, seven were newly-approved biologics, leading analysts to wonder whether 2009 was the year the biotech industry finally came into its own. The biggest NME winner was Novartis, which boasted four new approvals. The company was followed by Johnson & Johnson's Centocor Ortho Biotech and GlaxoSmithKline, with two approvals apiece. Slideshow ⇒